medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299532; this version posted December 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### Heart size disparity drives sex-specific response to cardiac resynchronization 1

#### therapy: a post-hoc analysis of the MORE-MPP CRT trial 2

## 3

#### Authors: 4

- 5
- 6
- Nadeev Wijesuriya <sup>1,2</sup>, Vishal Mehta <sup>1,2</sup>, Felicity De Vere <sup>1,2</sup>, Sandra Howell<sup>1,2</sup>, Steven A Niederer <sup>1,3</sup>, Haran Burri<sup>4</sup>, Johannes Sperzel<sup>5</sup>, Leonardo Calo<sup>6</sup>, Bernard Thibault<sup>7</sup>, 7
- Wenjiao Lin<sup>8</sup>, Kwangdeok Lee<sup>8</sup>, Andrea Grammatico<sup>8</sup>, Niraj Varma<sup>9</sup>, Marianne 8
- Gwechenberger<sup>10</sup>, Christophe Leclercg<sup>11</sup>, Christopher A Rinaldi<sup>1,2,9</sup> 9
- 10

Affiliations: 11

- 12
- <sup>1</sup> Kina's College London, UK 13
- <sup>2</sup> Guy's and St Thomas's NHS Foundation Trust, London, UK 14
- <sup>3</sup> National Heart and Lung Institute, Imperial College London, UK 15
- <sup>4</sup> University Hospital of Geneva, Geneva, Switzerland 16
- <sup>5</sup> Kerckhoff Klinik Heart Center, Bad Nauheim, Germany 17
- <sup>6</sup> Casilino Policlinico, Rome, Italy 18
- <sup>7</sup> Montreal Heart Institute, Montreal, QC, Canada 19
- <sup>8</sup> Abbott, Plano, TX, United States 20
- <sup>9</sup> Cleveland Clinic, London, UK 21
- <sup>10</sup> Medical University of Vienna, Austria 22
- <sup>11</sup> CHRU Pontchaillou, Rennes, France 23
- 24 25

### **Conflict of Interests / Funding Statement:** 26

27

The NW, VM, FdV, and SH are supported by the Wellcome/EPSRC Centre for 28

- Medical Engineering (WT203148/Z/16/Z). NW receives fellowship funding from the 29
- British Heart Foundation (FS/CRTF/22/24362). SAN acknowledges support from the 30
- UK Engineering and Physical Sciences Research Council (EP/M012492/1, 31
- NS/A000049/1, and EP/P01268X/1), the British Heart Foundation 32
- (PG/15/91/31812,PG/13/37/30280, SP/18/6/33805), US National 33
- Institutes of Health (NIH R01-HL152256), European Research Council (ERC 34
- 35 PREDICT-HF 864055) and Kings Health Partners London National Institute for
- 36 Health Research (NIHR) Biomedical Research Centre. BT receives research support
- from Abbott. MG received lecture and/or consultation fees from Abbott. Medtronic. 37
- 38 Boston Scientific, Biotronik and MicroPort. CL receives speaker fees from Medtronic,
- 39 Abbott and Biotronik. CAR receives research funding and/or consultation fees from
- Abbott, Medtronic, Boston Scientific, Spectranetics, EBR Systems and MicroPort 40
- outside of the submitted work. 41
- 42
- Corresponding author 43
- 44 Dr Nadeev Wijesuriva
- School of Biomedical Engineering and Imaging Sciences, Rayne Institute, 4th Floor 45
- Lambeth Wing, St Thomas's Hospital, Westminster Bridge Road, London SE1 7EH 46
- 47 Email: nadeev.wijesuriya@kcl.ac.uk
- 48
- 49 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 50 51 <u>Abstract</u>

52

53 Background: Studies have reported that female sex predicts superior cardiac

54 resynchronization therapy (CRT) response. One theory is that this association is

55 related to smaller female heart size, thus increased "relative dyssynchrony" at given

- 56 QRS durations (QRSd).
- 57 *Objective*: To investigate the mechanisms of sex-specific CRT response relating to

heart size, relative dyssynchrony, cardiomyopathy type, QRS morphology, and otherpatient characteristics.

60 *Methods*: A post-hoc analysis of the MORE-CRT MPP trial (n=3739, 28% female),

61 with a sub-group analysis of patients with non-ischaemic cardiomyopathy (NICM)

and left bundle branch block (LBBB) (n=1308, 41% female) to control for

63 confounding characteristics. A multivariable analysis examined predictors of

response to 6 months of conventional CRT, including sex and relative dyssynchrony,

65 measured by QRSd/LVEDV (left ventricular end-diastolic volume).

66 *Results*: Females had a higher CRT response rate than males (70.1% vs. 56.8%,

67 p<0.0001). Subgroup analysis: Regression analysis of the NICM LBBB subgroup

68 identified QRSd/LVEDV, but not sex, as a modifier of CRT response (p<0.0039).

69 QRSd/LVEDV was significantly higher in females (0.919) versus males (0.708,

p<0.001). CRT response was 78% for female patients with QRSd/LVEDV>median

value, compared to 68% < median value (p=0.012). Association between CRT

response and QRSd/LVEDV was strongest at QRSd<150ms.

73 *Conclusions:* In the NICM LBBB population, increased relative dyssynchrony in

females, who have smaller heart sizes than their male counterparts, is a driver of

sex-specific CRT response, particularly at QRSd <150ms. Females may benefit from

76 CRT at a QRSd <130ms, opening the debate on whether sex-specific QRSd cut-offs

or QRS/LVEDV measurement should be incorporated into clinical guidelines.

78

79

80 81

82

84

#### Introduction 85

86

87 Cardiac Resynchronization Therapy (CRT) is a hallmark treatment for patients with 88 dyssynchronous heart failure.(1) However, despite its widespread success and uptake, 30% of patients fail to derive benefit.(2,3) These "CRT non-responders" have 89 90 amongst the poorest long-term outcomes of any subgroup in the heart failure population.(4) As such, there is significant interest in examining factors which 91 92 modulate CRT response. It has been well established that certain conditions are associated with a poorer 93 94 clinical or LV remodelling responses to CRT, for example, ischaemic cardiomyopathy, atrial fibrillation (AF) and non-left bundle branch block (LBBB) QRS morphology.(5) 95 96 These associations are unsurprising from a physiological perspective. An area which remains poorly understood is the association of male or female sex in CRT 97 response. Although some studies report no sex differences, for example CARE-98 HF(6) most have reported that female sex is predictive of superior clinical and 99 100 echocardiographic response.(7–12) In a meta-analysis of 149,259 patients, Yin et al. 101 observed a lower all-cause mortality in females than males post-CRT (odds ratio[OR] 102 0.50, 95% confidence interval [CI] 0.36 to 0.70).(13) Females also exhibited

103 statistically significant improvement in left ventricular ejection fraction (LVEF) and 104 decrement of left ventricular end-diastolic diameter (LVEDD) when compared with

105 males.

The mechanisms underpinning this association remain unclear. One theory is that 106

107 the higher female response rate is related to a higher frequency of LBBB and non-

108 ischaemic cardiomyopathy (NICM) phenotypes. Determining this accurately requires

109 examination of large sample sizes, especially as women represent only 20-30% of

the population in CRT trials.(14) 110

Sex-related CRT response disparity may also be explained by differences in cardiac 111 size,(15) that is, that females are relatively smaller than males, and therefore have a 112 greater degree of dyssynchrony at a given QRSd. This is supported by studies that 113 report that females exhibit an improved CRT response compared to males in cohorts 114 with a QRSd <150ms.(16–18). It is suggested that sex-specific differences in QRS-115 response relationship are unexplained by the application of strict LBBB criteria or by 116 body surface area, but resolved by QRSd "normalization" for heart size using LV 117

118 mass or LV end diastolic volume (LVEDV).(19,20) These metrics of "relative

dyssynchrony" such as QRSd/LVEDV are not routinely measured in clinical practice,

nor are they frequently reported in larger CRT trials. As such, this area has to date

only been examined in single-center cohorts with small sample sizes. A meta-

analysis of 3496 patients identified height and QRS duration, but not sex, as

123 independent predictor for the composite outcome of first hospitalisation for heart

124 failure and all-cause mortality, however, QRSd/LVEDV was not used in this

125 analysis.(21)

126

127 In this study, we aimed to determine the association between sex, LV size and

relative dyssynchrony in a large cohort of CRT recipients. We tested this by

129 performing a sub-analysis of patients recruited to the MORE-CRT MPP trial.

130

# 131 <u>Methods</u>

132

MORE-CRT MPP is a prospective, randomized, multicenter study.(22,23) All patients
initially receive conventional biventricular (BiV) CRT for 6 months. At this stage,
echocardiographic non-responders are randomized to either continued conventional

BiV pacing, or multi-point pacing. CRT response was defined as a reduction in LV

end systolic volume (LVESV) >15% analysed by an independent core lab. We

evaluated data following the first 6 months of conventional BiV CRT; a post-hoc

139 multivariable analysis examined predictors of this reverse remodelling response

140 (Supplement Figure 1). In particular we assessed the predicted probability of CRT

141 response according to sex and QRSd/LVEDV. A subgroup analysis of the NICM

142 LBBB population was performed to test the effect without confounding from

significant variables such as QRS morphology and cardiomyopathy phenotype.

144

# 145 Study participants

The study enrolled eligible patients with a standard CRT indication after obtaining
written informed consent. The device was programmed BiV pacing in those patients
who had the quadripolar CRT system successfully implanted (Quartet LV lead with a
Quadra CRT device, Abbott, Sylmar, CA, USA) with programming of the LV pacing

150 vector, A-V delay, and V-V delay settings at the implanting physician's discretion.

151 During the first 6 months following implant, all subjects received standard BiV

- 152 pacing.
- 153

### 154 Echocardiographic assessment

Trained and qualified site personnel performed echocardiographic recordings, with analysis performed by an independent Echocardiography Core Laboratory. The core laboratory averaged the LV volumes measured in the apical two-chamber view and four-chamber view and measured LVEF. All measurements were made at baseline and at 6 months.

160

### 161 Statistics

162 Summary statistics were used for baseline characteristics. Continuous variables

163 were summarized by means and SD. Two-sample student's t-test or Wilcoxon rank

sum test was used to test the difference between 2 groups depending on the

normality of the data. Frequencies and percentages summarized categorical

- 166 variables. Chi-square test or Fisher exact test was used to test the difference
- 167 between groups.

168 We performed univariable models using the following baseline variables: age, AF,

169 chronic obstructive pulmonary disease (COPD), diabetes, hypercholesterolaemia,

170 hypertension, LVEDV, LVEF, New York Heart Association (NYHA) Class I/II versus

171 NYHA III/IV, renal disease, ischaemic versus NICM, LBBB versus non-LBBB, QRSd,

- 172 QRSd/LVEDV ("normalised QRS) and sex. Multivariable models were conducted
- using stepwise selections. The criteria for baseline variables entering and staying

into model was  $\alpha$ =0.25 and  $\alpha$ =0.05, respectively. Age and gender were forced into

the model. Given that logistic regression methods relies upon the assumption of

176 linearity between CRT response and the predicting independent variables (patients'

177 characteristics) we also evaluated the probability of CRT response as a function of

178 QRSd (divided in 5 subgroups) and as a function of QRSd normalized by dividing it

by LVEDV (divided in 10 deciles) to account for heart size differences between

180 females and males. The predicted probability of CRT response as a function of

181 QRSd and normalised QRSd was derived from multivariable logistic regression

182 models. Analyses were conducted using SAS<sup>®</sup> 9.4.

- 183
- 184

185 186 187 **Results** 188 189 **Baseline Characteristics** The analysis was performed on 3739 patients (1051, 28% female). Patient baseline 190 191 characteristics are shown in Tables 1 and 2. In the whole population (Table 1), the cardiac size in females was significantly smaller compared to males (176±60 ml vs. 192 193 228  $\pm$ 77 ml, p<0.0001). Females had a significantly shorter QRSd than males (153±22 ms vs.158±26 ms, p<0.0001). Similar results on cardiac size and QRSd 194 195 were observed in the non-ischemic LBBB subgroup (Table 2), 196 197 CRT response in the whole study cohort CRT response by sex is outlined in Table 3. Female patients had a higher CRT 198 response rate than males in the total population (70.1% vs. 56.8%, p<0.0001). The 199 results of the logistic regression model (Table 4) show that LBBB, wide QRSd, and 200 201 female sex are significant independent predictors for improved response while 202 history of AF, ischemic aetiology, large heart (LVEDV), and history of renal disease 203 are significant independent predictors for reduced CRT response. When 204 QRSd/LVEDV ratio instead of QRSd was included in a separate model, 205 QRSd/LVEDV was not a significant independent predictor of response (OR 1.21 95% 206 CI 0.89-1.63, p=0.22). 207 208 CRT response in NICM LBBB cohort 209 In a subgroup analysis of only patients with a NICM LBBB phenotype (1308 patients, 210 538 female), there was no significant difference in CRT response between males and females (73% vs 70%, p=0.25). A logistic regression model (Table 5) when 211 applied to NICM LBBB patients showed that CRT response was significantly and 212 independently associated with QRSd/LVEDV but not with sex. Normalised QRS was 213 significantly different between females, who had median value of 0.919 (0.734-214 1.127) ms/ml, and males who had median value of 0.708 (0.585-0.886) ms/ml 215 (p<0.001). For female patients with a QRSd/LVEDV of >0.915ms/ml (the median 216

value), the CRT response rate was 78%, compared to 68% in patients where the

- 218 QRSd/LVEDV was below the median value (p=0.012, Figure 1). CRT response as a function of QRSd/LVEDV for male patients is shown in Supplemental Figure 2. 219
- 220

### Analysis of sex-impact as a function of QRS in NICM LBBB cohort 221

222

In a further analysis of CRT response as a function of QRSd in patients with NICM 223

- 224 and LBBB and the female CRT response rate was statistically superior to that of males (69.7% vs. 56.9%, p = 0.015) at QRSd < 150ms (n=315, with 54 patients 225
- 226 displaying QRSd < 130ms) see Figure 2). The predicted probability of CRT
- response, estimated by the logistic regression model, shows that CRT response 227
- 228 improves diminishing LVEDV and increasing QRSd/LVEDV and that at QRSd
- 229 <150ms female patients have higher CRT response vs. male patients (Figure 3). . A
- QRSd/LVEDV of 1.54 in patients with NICM, LBBB, and QRSd < 150ms [AUC: 0.62, 230
- 95% CI: 0.56-0.69; p=0.0002] was the optimal cut point predicting at least 80% CRT 231
- response, based on ROC analysis using the point on the curve closer to the upper 232
- left corner (Supplement Figure 3). Instead, when considering the entire spectrum of 233
- 234 QRS durations, no difference in the predicted probability of CRT response was
- 235 observed between the genders (Supplement Figure 4).
- Further parametric estimates are displayed in Figure 4, showing that the cohort with 236
- 237 the highest predicted CRT response are female patients with an LVEDV < the
- median value, "smaller" heart size. The difference between male and female patents 238
- 239 is not significant at larger heart sizes.
- Females with smaller heart size had a significantly higher CRT response than all 240
- 241 three other cohorts (Supplement Table 1): females with a larger heart size (OR 1.87,
- 242 95% CI 1.26-2.77); males with a small heart size (OR 1.61 95% CI 1.11-2.33) and
- 243 males with a large heart size (OR 1.92, 95% CI 1.31-2.82).
- 244
- 245

### Discussion 246

- We describe here a post-hoc analysis from the prospective multicenter MORE-CRT 247
- MPP, a large trial of 3739 participants, all with complete echocardiographic data 248
- 249 available at baseline and 6 months. This large sample size allowed associations
- 250 between CRT reverse remodelling response and characteristics such as sex to be
- reliably determined, as well as provided the opportunity to analyze normalised QRS, 251

- a baseline variable which is difficult to examine without complete imaging datasets.
- 253 Importantly, we report results from the largest dataset of female CRT patients ever
- evaluated so far.(14) Our findings were as follows:
- 255
- 1. CRT response was superior in females in the *overall cohort*.
- 257 2. In the *NICM LBBB cohort*, female sex was not an independent response258 predictor.
- 3. In the *NICM LBBB cohort,* increasing normalised QRSd is a significant
  independent response predictor.
- 261 4. In the *NICM LBBB cohort*, CRT response was superior in females at QRSd <
- 150 ms and the association between normalised QRSd and response is
- strongest at QRSd <150ms.
- 264

## 265 Female sex and CRT response

- In the MORE-CRT MPP population, CRT response was overall superior amongst
  female patients, supporting data from previous studies.(7–12) Our primary logistic
  regression analysis identified the female sex as a significant positive CRT response
  modifier, as well as the absence of AF, NICM, LBBB, and the absence of renal
  disease. Interestingly, however, when a subgroup analysis of 1308 patients with
- 271 NICM and LBBB was performed to control for the effects of cardiomyopathy
- 272 phenotype and QRS morphology, there was no significant difference in CRT
- 273 response between female and male patients.
- 274 There is conflicting evidence for whether sex is truly an independent modifier of
- response or whether it is related to confounding variables. Arshad et al(24)
- suggested from a post-hoc analysis of the MADIT-CRT trial that sex discrepancy was
- 277 related to a higher proportion of NICM LBBB patients in females, factors that are
- 278 well-established as being beneficial in CRT response. Whilst previous studies have
- 279 reported that the female sex may be an independent CRT response modifier, it is
- important to note the limitations of logistic regression analyses. Use of logistic
- regression to examine this association may be limited by several factors, such as:
- small female sample size in CRT trials; the assumption of linearity between female
- sex and CRT response; and the assumption of average or low multicollinearity
- between dependent and independent variables, such as sex and LVEDV.(25) Our
- analysis of a large subgroup of NICM LBBB patients is consistent with the theory that

It is made available under a CC-BY 4.0 International license .

Our analysis has demonstrated that the sex-specific divergence in CRT response is

the female sex is not *independently* associated with CRT response, but rather, is
related to confounding from positive response modifiers, such as NICM and LBBB.

289 Sex-specific impact of QRS, heart size and CRT response

290

291 most pronounced at shorter QRSd. This supports two previous secondary analyses 292 from the MADIT-CRT study which reported that amongst patients with QRSd <150ms, only females derived benefit from CRT compared to ICD.(26,27) 293 294 The reasons for this may lie in the discrepancy between male and female heart size, 295 and thus, "relative dyssynchrony", measured by normalised QRSd. Indeed we 296 demonstrate that in the subgroup of NICM LBBB patients, QRSd/LVEDV is a 297 significant predictor of CRT response. This association is strongest at narrower QRSd and smaller heart sizes. We suggest therefore that the sex-specific 298 differences in CRT response in this subpopulation are a result of increased relative 299 300 dyssynchrony in the females with narrow QRSd, but reduced heart size compared to 301 their male counterparts, and thus, an increased QRSd/LVEDV ratio. This supports 302 previous smaller studies which have suggested that normalized QRSd may be an 303 appropriate target to guide CRT implantation, (19–21) and mechanistic studies which have reported that echo-derived dyssynchrony was more predictive of CRT response 304 305 than absolute QRSd, and may be beneficial in patients with a narrow QRSd.(28,29) 306 Furthermore, a post-hoc analysis of the ECHO-CRT trial, a study which reported 307 futility in patients with a narrow QRSd implanted with CRT, reported that: 1) males formed the majority of patients and they drove the negative outcome, while CRT-ON 308 309 vs. CRT-OFF comparison was neutral in females; 2) the higher risk of negative 310 outcome was concentrated among those with larger LV dimensions and 3) CRT. 311 compared with the control group, induced significant LV reverse remodelling in patients with large normalized QRSd/LVEDV (>1.3 ms/ml).(30) 312 It should be noted that our results indicate that the strength of the correlation 313 between sex and CRT response appears to be attenuated at very high QRSd. We 314 315 theorize that this is because at these high levels of relative dyssynchrony, CRT 316 response rates are high in both sexes (approximately 70-75%). Therefore, despite increased QRSd/LVEDV in female patients at these levels, alternative issues are 317 likely to be driving non-response, thus diminishing the effect of sex on CRT efficacy 318 at the high extremes of QRSd. 319

321

### 322 Clinical implications

323 This study demonstrates that heart size is an important factor in driving sex-specific

- 324 CRT response, in view of increased normalised QRSd in female patients, with the
- 325 benefit predominant at narrower QRS durations. These associations were observed
- through a sub-group analysis of the NICM LBBB cohort which mitigated noise from
- 327 confounding variables.
- 328 Within an NICM LBBB population, selecting CRT recipients based on absolute QRSd
- 329 dichotomization may exclude certain female patients who could benefit from
- treatment based on a high degree of relative dyssynchrony due to small heart size.
- 331 Current European and US guidelines define QRSd cut-offs of 130ms and 120ms
- respectively, as the target criteria for CRT implantation.(1,31,32) These cut-offs are
- 333 defined from meta-analyses of studies with few female participants, which may hide
- a possible beneficial effect of CRT in female patients with narrower QRSd.(33) This
- study opens the debate on whether the use of normalized QRSd should be
- integrated into routine clinical practice to identify these patients. Alternatively, sex-
- 337 specific QRSd cut-offs may be considered as a practical surrogate accounting for the
- 338 significant disparities in normalised QRSd.
- 339

# 340 Limitations

341

This study represents a retrospective analysis of the observational MORE-CRT MPP 342 343 trial. As such, we cannot exclude inherent limitations associated with observational 344 studies, such as selection bias. Nevertheless, the study has important strengths: 1) 345 data collection was prospective; 2) analyses objectives were prespecified; 3) monitoring with strict source data verification activities; 4) echocardiographic 346 evaluations by an echo core lab and 5) the large sample size allowed us to control 347 for confounding patient characteristics, such as ischemic vs non-ischemic 348 cardiomyopathy or LBBB vs. non-LBBB QRS morphology. Overall, we are confident 349 that the study data provides a fair description of current CRT application and 350 351 outcomes, however, our conclusions should be interpreted as hypothesis generating. 352 Acknowledgment 353

- The authors thank all investigators, the staff, and the participants of the MORE CRT
- MPP trial for their valuable contributions. A full list of participating principal
- investigators and institutions can be found in Supplemental Table 2.

#### **TABLES**

Table 1 – Baseline patient characteristics for the whole population. LBBB = Left Bundle Branch Block; COPD = Chronic Obstructive Pulmonary Disease; ACE = Angiotensin-converting enzyme; ARB = Angiotensin II receptor blocker; \*Wilcoxon rank sum test, <sup>†</sup>Pearson chi-square test 

		Female		
	All Subjects	Subjects	Male Subjects	
Demographic Variable	(N=3,739)	(N=1,051)	(N=2,688)	P value
Age (Years)	00 . 11	00 + 11	00 . 44	0.0454
Mean ± SD	68 ± 11	68 ± 11	68 ± 11	0.3454*
NYHA Class at Enrolment (%)				
Class II	51.2	45.3	53.5	
Class III	46.6	52.1	44.5	<0.0001 <sup>+</sup>
Class IV	1.9	2.4	1.7	
QRS Duration (ms)				
Mean ± SD (n)	156 ± 25	153 ± 22	158 ± 26	<0.0001*
QRS Morphology (%)				
LBBB	70.2	79.5	66.4	<0.0001 <sup>†</sup>
Non-LBBB	29.8	20.5	33.6	<0.0001
Cardiomyopathy Etiology (%)				
Ischemic	41.0	22.0	48.4	-0.0004t
Non-Ischemic	59.0	78.0	51.6	<0.0001
LVESV (ml)				
Mean ± SD	160 ± 65	131 ± 52	171 ± 66	<0.0001*
LVEDV (ml)				
Mean ± SD	214 ± 76	176 ± 60	228 ± 77	<0.0001*
LVEF (%)				
Mean ± SD	26 ± 7	27 ± 7	26 ± 7	0.0965*
Device Type (%)				
CRT-P	12.2	16.9	10.4	-0.0004+
CRT-D	87.8	83.1	89.6	<0.0001
Medical History (%)				
Hypertension	62.3	59.0	63.6	0.0087 <sup>+</sup>
Hypercholesterolemia	40.1	34.6	42.2	<0.0001 <sup>†</sup>
Diabetes	33.4	30.4	34.6	0.0126 <sup>†</sup>
COPD	10.6	8.5	11.5	0.0076†
Renal Disease	15.0	11.4	16.4	0.0001 <sup>+</sup>
Medical Treatment (%)				
Diuretics	77.4	79.5	76.5	0.0474 <sup>+</sup>
ACE inhibitor or ARB	89.3	89.4	89.2	0.8400 <sup>†</sup>
β-Blocker	89.1	89.2	89.1	0.8697†
Aldosterone antagonist	38.9	38.5	39.1	0.7660 <sup>†</sup>
Anticoagulant	26.9	21.4	29.1	<0.0001 <sup>†</sup>
Calcium Channel Blockers	7.9	6.2	8.6	0.0156†
Nitrates	7.4	5.6	8.1	0.0097†

#### Table 2 – Baseline patient characteristics for non-ischemic LBBB patients.

COPD = Chronic Obstructive Pulmonary Disease; ACE = Angiotensin-converting enzyme; ARB = Angiotensin II receptor blocker; \*Wilcoxon rank sum test, <sup>†</sup>Pearson chi-square test 

	All Subjects	Female Subjects	Male Subjects	
Demographic Variable	(N=1,308)	(N=538)	(N=770)	P value
Age (Years)				
Mean ± SD	66 ± 11	67 ± 10	65 ± 11	0.0039*
NYHA Class at Enrolment (%)				
Class II	55.4	45.5	62.2	
Class III	42.2	51.5	35.7	<0.0001 <sup>+</sup>
Class IV	2.1	2.6	1.8	
QRS Duration (ms)				
Mean ± SD (n)	161 ± 19	157 ± 18	165 ± 20	<0.0001*
LVESV (ml)				
Mean ± SD	162 ± 70	135 ± 54	181 ± 73	<0.0001*
LVEDV (ml)				
Mean ± SD	216 ± 82	180 ± 64	241 ± 85	<0.0001*
LVEF (%)				
Mean ± SD	26 ± 7	26 ± 7	26 ± 7	0.3278*
Device Type (%)				
CRT-P	11.3	13.9	9.5	0.0100
CRT-D	88.7	86.1	90.5	0.0122
Medical History (%)				
Hypertension	56.4	55.0	57.4	0.3922 <sup>†</sup>
Hypercholesterolemia	33.1	29.9	35.3	0.0412 <sup>+</sup>
Diabetes	28.4	29.4	27.8	0.5342 <sup>+</sup>
COPD	9.7	8.9	10.3	0.4213†
Renal Disease	9.2	9.1	9.2	0.9445†
Medical Treatment (%)				
Diuretics	76.6	78.8	75.1	0.1154†
ACE inhibitor or ARB	91.5	90.7	92.1	0.3811†
β-Blocker	91.1	90.3	91.6	0.4454†
Aldosterone antagonist	40.0	38.3	41.2	0.2956†
Anticoagulant	21.0	17.7	23.4	0.0125 <sup>†</sup>
Calcium Channel Blockers	5.0	5.2	4.9	0.8266†
Nitrates	3.7	3.5	3.8	0.8242 <sup>†</sup>

#### Table 3 - CRT response by sex

Population	Gender	6M Responder Rate(n/N)	p-value
Whole Population	F	70.12% (737/1051)	<.0001
	М	56.85% (1528/2688)	
LBBB Patients	F	71.07% (479/674)	<.0001
	М	62.06% (854/1376)	
Non-ischemic LBBB Patients	F	73.05% (393/538)	0.2508
	М	70.13% (540/770)	
Non-ischemic LBBB and QRSd<150ms	F	69.71% (122/175)	0.0157
	М	56.86% (87/153)	
Non-LBBB Patients	F	62.64% (109/174)	<.0001
	М	40.29% (280/695)	

### 

## Table 4 - Logistic regression results (whole population)

	Univeriete			Multivariate (2966 pat	ionto)
	Univariate		-	wullivariale (2000 pai	ients)
Parameter	Parameter Estimate	р	Sample	Parameter Estimate	p value
	[95% CI]	value	Size	[95% CI]	
Age	0.998 [0.992, 1.004]	0.5685	3,738	1.002 [0.994, 1.010]	0.6972
Atrial fibrillation	0.679 [0.565, 0.815]	<.0001	3,739	0.785 [0.627, 0.982]	0.0339
COPD	1.018 [0.822, 1.260]	0.8702	3,739		
Diabetes	0.770 [0.671, 0.884]	0.0002	3,739		
Hypercholesterolemia	0.813 [0.712, 0.929]	0.0024	3,739		
Hypertension	1.047 [0.914, 1.198]	0.5096	3,739		
Ischemic vs	0.502 [0.439, 0.574]	<.0001	3,739	0.550 [0.466, 0.648]	<.0001
Non-Ischemic					
LBBB vs Non-LBBB	2.294 [1.952, 2.696]	<.0001	2,919	1.911 [1.593, 2.291]	<.0001
LVEDV	0.999 [0.998, 1.000]	0.0024	3,739	0.998 [0.997, 0.999]	0.0035
LVEF	0.996 [0.987, 1.005]	0.4062	3,739		
NYHA I/II vs III/IV	1.267 [1.111, 1.445]	0.0004	3,728		
QRSd	1.007 [1.005, 1.010]	<.0001	3,223	1.005 [1.001, 1.008]	0.0107
Renal Disease	0.569 [0.475, 0.682]	<.0001	3,739	0.663 [0.532, 0.826]	0.0002
Female vs Male	1.782 [1.530, 2.075]	<.0001	3,739	1.385 [1.144, 1.675]	0.0008

### Table 5 - Logistic regression results (non-ischaemic left bundle branch block population)

	Univariate			Multivariate (1295 pat	tients)
Parameters	Parameter Estimate [95% CI]	p-value	Sample Size	Parameter Estimate [95% CI]	p-value
Age	1.002 [0.991, 1.013]	0.7481	1308	1.000 [0.988, 1.012]	0.9983
AF vs No AF	0.651 [0.449, 0.945]	0.0240	1308	0.627 [0.430, 0.913]	0.0150
COPD Yes vs No	1.400 [0.908, 2.158]	0.1275	1308		
Diabetes Yes vs No	0.759 [0.585, 0.985]	0.0378	1308	0.751 [0.577, 0.978]	0.0333
Hypercholesterolemia	0.922 [0.715, 1.187]	0.5278	1308		
Hypertension Yes vs No	0.994 [0.780, 1.265]	0.9590	1308		
LVEDV	0.998 [0.997, 0.999]	0.0041	1308		
LVEF	1.009 [0.991, 1.026]	0.3307	1308		
NYHA I/II vs NYHA III/IV	1.115 [0.876, 1.419]	0.3751	1304		
QRSd	1.010 [1.004, 1.016]	0.0022	1295		
QRSd/LVEDV	1.948 [1.267, 2.996]	0.0024	1295	1.984 [1.246, 3.157]	0.0039
Renal Disease Yes vs No	0.616 [0.417, 0.909]	0.0147	1308		
Female vs Male	1.154 [0.903, 1.475]	0.2509	1308	0.987 [0.758, 1.285]	0.9202





Figure 2 - CRT response in patients with NICM and LBBB as a function of QRSd. QRSd was treated as a continuous variable, divided in 5 strata, as follows: strata 1 -QRSd<130ms; strata 2 - QRSd≥130 and <150 ms; strata 3 patients with QRSd≥150 ms and <170 ms, strata 4 patients with QRSd≥170 ms and <190 ms, strata 5 patients with QRSd  $\geq$  190ms. 



medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299532; this version posted December 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

420 Figure 3 - Parametric estimates with corresponding 95% confidence intervals showing predicted CRT response as function of LVEDV (top 2 panels) and 421 normalised QRSd (bottom 2 panels). The left panels display data for patients with 422 QRSd <150ms, and the right panels for those with QRSd >150ms. Blue (with 95% 423 CI): female patients, red (with 95% CI): male patients. 424

425



Figure 4 - Parametric estimates with corresponding 95% confidence interval showing predicted CRT response as function of QRSd in 4 subgroups: females with heart size above and below median LVEDV of 168.5ml, and males with heart size above and below median LVEDV of 227.6ml. 



medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299532; this version posted December 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY 4.0 International license .

#### 454 **REFERENCES**

- 455
- 456 1. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et 457 al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization 458 therapyDeveloped by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With 459 460 the special contribution of the European Heart Rhythm Association (EHRA). EP Europace [Internet]. 2022 Jan 4 [cited 2023 May 15];24(1):71-164. 461 462 Available from: https://academic.oup.com/europace/article/24/1/71/6358627 463 2. Young JB. Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure. JAMA. 2003 464 May 28;289(20):2685. 465 466 3. Varma N, Boehmer J, Bhargava K, Yoo D, Leonelli F, Costanzo M, et al. Evaluation, Management, and Outcomes of Patients Poorly Responsive to 467 Cardiac Resynchronization Device Therapy. J Am Coll Cardiol [Internet]. 2019 468 Nov 26 [cited 2023 Oct 13];74(21):2588-603. Available from: 469 470 https://www.jacc.org/doi/10.1016/j.jacc.2019.09.043 4. Vijavaraman P. Herweg B. Verma A. Sharma PS. Batul SA. Ponnusamy SS. et 471 al. Rescue left bundle branch area pacing in coronary venous lead failure or 472 473 nonresponse to biventricular pacing: Results from International LBBAP 474 Collaborative Study Group. Heart Rhythm. 2022 Aug 1; Sieniewicz BJ, Gould J, Porter B, Sidhu BS, Teall T, Webb J, et al. 475 5. 476 Understanding non-response to cardiac resynchronisation therapy: common 477 problems and potential solutions. Heart Fail Rev [Internet]. 2019 Jan 1 [cited 478 2022 Sep 2];24(1):41–54. Available from: 479 https://link.springer.com/article/10.1007/s10741-018-9734-8 480 6. Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac 481 482 Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail [Internet]. 483 2012 Jun 1 [cited 2023 Oct 13];14(6):628–34. Available from: https://onlinelibrary.wiley.com/doi/full/10.1093/eurjhf/hfs055 484 7. Cheng A, Gold MR, Waggoner AD, Meyer TE, Seth M, Rapkin J, et al. 485 Potential mechanisms underlying the effect of gender on response to cardiac 486 487 resynchronization therapy: Insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May 1;9(5):736-41. 488 Lilli A, Ricciardi G, Porciani MC, Perini AP, Pieragnoli P, Musilli N, et al. Cardiac 489 8. Resynchronization Therapy: Pacing and Clinical Electrophysiology [Internet]. 490 2007 Nov 1 [cited 2023 Jun 5];30(11):1349–55. Available from: 491 492 https://onlinelibrary.wiley.com/doi/full/10.1111/j.1540-8159.2007.00870.x 493 9. Kirubakaran S, Ladwiniec A, Arujuna A, Ginks M, McPhail M, Bostock J, et al. Male gender and chronic obstructive pulmonary disease predict a poor clinical 494 495 response in patients undergoing cardiac resynchronisation therapy. Int J Clin Pract [Internet]. 2011 Mar 1 [cited 2023 Jun 5];65(3):281-8. Available from: 496 https://onlinelibrary.wiley.com/doi/full/10.1111/j.1742-1241.2010.02491.x 497 498 10. Leyva F, Foley PWX, Chalil S, Irwin N, Smith REA. Female Gender is Associated with a Better Outcome after Cardiac Resynchronization Therapy. 499 Pacing and Clinical Electrophysiology [Internet]. 2011 Jan 1 [cited 2023 Jun 500 501 5];34(1):82–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1540-8159.2010.02909.x 502

medRxiv preprint doi: https://doi.org/10.1101/2023.12.05.23299532; this version posted December 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 503 11. Van Bommel RJ, Bax JJ, Abraham WT, Chung ES, Pires LA, Tavazzi L, et al. Characteristics of heart failure patients associated with good and poor 504 505 response to cardiac resynchronization therapy: a PROSPECT (Predictors of 506 Response to CRT) sub-analysis. Eur Heart J [Internet]. 2009 Oct 1 [cited 2023] 507 Jun 5];30(20):2470–7. Available from: https://academic.oup.com/eurhearti/article/30/20/2470/428761 508
- 509 12. Providencia R, Marijon E, Barra S, Reitan C, Breitenstein A, Defaye P, et al. 510 Usefulness of a clinical risk score to predict the response to cardiac 511 resynchronization therapy. Int J Cardiol. 2018 Jun 1;260:82–7.
- 512 13. Yin FH, Fan CL, Guo YY, Zhu H, Wang ZL. The impact of gender difference on clinical and echocardiographic outcomes in patients with heart failure after 513 cardiac resynchronization therapy: A systematic review and meta-analysis. 514 515 PLoS One [Internet]. 2017 Apr 1 [cited 2023 Jun 5];12(4):e0176248. Available 516 from:
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176248 517
- Ahmad J, Ahmad HA, Surapaneni P, Penagaluri A, Desai S, Dominic P. 14. 518 519 Women are underrepresented in cardiac resynchronization therapy trials. J 520 Cardiovasc Electrophysiol [Internet]. 2022 Dec 1 [cited 2023 Jun 26];33(12):2653-7. Available from: 521
- 522 https://onlinelibrary.wiley.com/doi/full/10.1111/jce.15715
- 523 15. De Simone G, Devereux RB, Daniels SR, Meyer RA. Gender Differences in Left Ventricular Growth. Hypertension [Internet]. 1995 [cited 2023 Jun 9];26(6 524 525 I):979–83. Available from:
- https://www.ahajournals.org/doi/abs/10.1161/01.HYP.26.6.979 526
- Varma N, Manne M, Nguyen D, He J, Niebauer M, Tchou P. Probability and 527 16. 528 magnitude of response to cardiac resynchronization therapy according to QRS 529 duration and gender in nonischemic cardiomyopathy and LBBB. Heart Rhythm. 2014 Jul 1;11(7):1139-47. 530
- De Pooter J, Kamoen V, El Haddad M, Stroobandt R, De Buyzere M, Jordaens 531 17. L, et al. Gender differences in electro-mechanical characteristics of left bundle 532 branch block: Potential implications for selection and response of cardiac 533 resynchronization therapy. Int J Cardiol. 2018 Apr 15;257:84–91. 534
- 535 18. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O'Callaghan KM, 536 Carpenter JL, et al. Cardiac resynchronization therapy in women: US Food 537 and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 538 [Internet]. 2014 [cited 2023 Jun 9];174(8):1340–8. Available from: 539 https://pubmed.ncbi.nlm.nih.gov/25090172/
- Varma N, Lappe J, He J, Niebauer M, Manne M, Tchou P. Sex-Specific 540 19. 541 Response to Cardiac Resynchronization Therapy: Effect of Left Ventricular 542 Size and QRS Duration in Left Bundle Branch Block. JACC Clin Electrophysiol 543 [Internet]. 2017 Nov 11 [cited 2023 Jun 5];3(8):844-53. Available from: https://www.jacc.org/doi/10.1016/j.jacep.2017.02.021 544
- Zweerink A, Friedman DJ, Klem I, van de Ven PM, Vink C, Biesbroek PS, et al. 545 20. Size Matters: Normalization of QRS Duration to Left Ventricular Dimension 546 547 Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. Circ Arrhythm Electrophysiol [Internet]. 2018 Dec 1 [cited 2023 Jun 548 5];11(12):e006767. Available from: 549

550 https://www.ahajournals.org/doi/abs/10.1161/CIRCEP.118.006767

551 21. Linde C, Cleland JGF, Gold MR, Claude Daubert J, Tang ASL, Young JB, et al. The interaction of sex, height, and QRS duration on the effects of cardiac 552

553 554 555		resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail [Internet]. 2018 Apr 1 [cited 2023 Jun 5]:20(4):780–91. Available from:
556		https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1133
557	22.	Leclercq C, Burri H, Delnoy PP, Rinaldi CA, Sperzel J, Calò L, et al. Cardiac
558		resynchronization therapy non-responder to responder conversion rate in the
559		MORE-CRT MPP trial, EP Europace [Internet], 2023 Oct 5 [cited 2023 Oct
560		17]:25(10):5-8. Available from: https://dx.doi.org/10.1093/europace/euad294
561	23.	Leclerca C. Investigators on behalf of the MCM. Burri H. Investigators on
562	-	behalf of the MCM. Curnis A. Investigators on behalf of the MCM. et al.
563		Cardiac resynchronization therapy non-responder to responder conversion
564		rate in the more response to cardiac resynchronization therapy with MultiPoint
565		Pacing (MORE-CRT MPP) study: results from Phase I. Eur Heart J [Internet].
566		2019 Sep 14 [cited 2023 Oct 17]:40(35):2979–87. Available from:
567		https://dx.doi.org/10.1093/eurhearti/ehz109
568	24.	Arshad A. Moss AJ. Foster E. Padeletti L. Barsheshet A. Goldenberg I. et al.
569		Cardiac resynchronization therapy is more effective in women than in men:
570		The MADIT-CRT (multicenter automatic defibrillator implantation trial with
571		cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011 Feb
572		15:57(7):813–20.
573	25.	Ranganathan P, Pramesh C, Aggarwal R. Common pitfalls in statistical
574		analysis: Logistic regression. Perspect Clin Res [Internet]. 2017 Jul 1 [cited
575		2023 Aug 11];8(3):148. Available from: /pmc/articles/PMC5543767/
576	26.	Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al.
577		Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in
578		the Multicenter Automatic Defibrillator Implantation Trial-Cardiac
579		Resynchronization Therapy (MADIT-CRT). Circulation [Internet]. 2011 Mar 15
580		[cited 2023 Aug 11];123(10):1061–72. Available from:
581		https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.110.960898
582	27.	Biton Y, Zareba W, Goldenberg I, Klein H, McNitt S, Polonsky B, et al. Sex
583		Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy
584		in Mild Heart Failure Patients With Left Bundle Branch Block. J Am Heart
585		Assoc [Internet]. 2015 Jun 29 [cited 2023 Aug 11];4(7). Available from:
586		https://www.ahajournals.org/doi/abs/10.1161/JAHA.115.002013
587	28.	Cazeau SJ, Daubert JC, Tavazzi L, Frohlig G, Paul V. Responders to cardiac
588		resynchronization therapy with narrow or intermediate QRS complexes
589		identified by simple echocardiographic indices of dyssynchrony: The DESIRE
590		study. Eur J Heart Fail [Internet]. 2008 Mar 1 [cited 2023 Jun 5];10(3):273–80.
591		Available from:
592		https://onlinelibrary.wiley.com/doi/full/10.1016/j.ejheart.2008.02.007
593	29.	Haghjoo M, Bagherzadeh A, Fazelifar AF, Haghighi ZO, Esmaielzadeh M,
594		Alizadeh A, et al. Prevalence of Mechanical Dyssynchrony in Heart Failure
595		Patients with Different QRS Durations. Pacing and Clinical Electrophysiology
596		[Internet]. 2007 May 1 [cited 2023 Jun 5];30(5):616–22. Available from:
597		https://onlinelibrary.wiley.com/doi/full/10.1111/j.1540-8159.2007.00722.x
598	30.	Varma N, Sogaard P, Bax JJ, Abraham WT, Borer JS, Dickstein K, et al.
599		Interaction of left ventricular size and sex on outcome of cardiac
600		resynchronization therapy among patients with a narrow QRS duration in the
601		EchoCRT trial. J Am Heart Assoc [Internet]. 2018 Jun 1 [cited 2023 Jun

	5];7(11). Available from:
	https://www.ahajournals.org/doi/abs/10.1161/JAHA.118.009592
31.	Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.
	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A
	Report of the American College of Cardiology/American Heart Association
	Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol [Internet].
	2022 May 3 [cited 2023 Aug 11];79(17):e263–421. Available from:
	https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012
32.	Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, et al.
	2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the
	avoidance and mitigation of heart failure. Heart Rhythm [Internet]. 2023 Sep 1
	[cited 2023 Oct 13];20(9):e17–91. Available from:
	https://onlinelibrary.wiley.com/doi/full/10.1002/joa3.12872
33.	Stavrakis S, Lazzara R, Thadani U. The Benefit of Cardiac Resynchronization
	Therapy and QRS Duration: A Meta-Analysis. J Cardiovasc Electrophysiol
	[Internet]. 2012 Feb 1 [cited 2023 Aug 11];23(2):163–8. Available from:
	https://onlinelibrary.wiley.com/doi/full/10.1111/j.1540-8167.2011.02144.x
	31. 32. 33.